key: cord-0704367-ium9jhc5
authors: Kwon, Jennie H; Tenforde, Mark W; Gaglani, Manjusha; Talbot, H Keipp; Ginde, Adit A; McNeal, Tresa; Ghamande, Shekhar; Douin, David J; Casey, Jonathan D; Mohr, Nicholas M; Zepeski, Anne; Shapiro, Nathan I; Gibbs, Kevin W; Files, D Clark; Hager, David N; Shehu, Arber; Prekker, Matthew E; Caspers, Sean D; Exline, Matthew C; Botros, Mena; Gong, Michelle N; Li, Alex; Mohamed, Amira; Johnson, Nicholas J; Srinivasan, Vasisht; Steingrub, Jay S; Peltan, Ithan D; Brown, Samuel M; Martin, Emily T; Khan, Akram; Hough, Catherine L; Busse, Laurence W; Duggal, Abhijit; Wilson, Jennifer G; Perez, Cynthia; Chang, Steven Y; Mallow, Christopher; Rovinski, Randal; Babcock, Hilary M; Lauring, Adam S; Felley, Laura; Halasa, Natasha; Chappell, James D; Grijalva, Carlos G; Rice, Todd W; Womack, Kelsey N; Lindsell, Christopher J; Hart, Kimberly W; Baughman, Adrienne; Olson, Samantha M; Schrag, Stephanie; Kobayashi, Miwako; Verani, Jennifer R; Patel, Manish M; Self, Wesley H
title: mRNA Vaccine Effectiveness Against COVID-19 Hospitalization Among Solid Organ Transplant Recipients
date: 2022-04-06
journal: J Infect Dis
DOI: 10.1093/infdis/jiac118
sha: 41c176be4f914259cbb6c86e5e19544d66a1119f
doc_id: 704367
cord_uid: ium9jhc5

BACKGROUND: The study objective was to evaluate 2 and 3 dose COVID-19 mRNA vaccine effectiveness (VE) in preventing COVID-19 hospitalization among adult solid organ transplant (SOT) recipients. METHODS: 21-site case-control analysis of 10,425 adults hospitalized March-December 2021. Cases were hospitalized with COVID-19; controls were hospitalized for an alternative diagnosis (SARS-CoV-2 negative). Participants were classified as: SOT recipient (n=440), other immunocompromising condition (n=1684), or immunocompetent (n=8301). VE against COVID-19 associated hospitalization was calculated as 1–adjusted odds ratio of prior vaccination among cases compared with controls. RESULTS: Among SOT recipients, VE was 29% (95% CI: -19 to 58%) for 2 doses and 77% (95% CI: 48 to 90%) for 3 doses. Among patients with other immunocompromising conditions, VE was 72% (95% CI: 64 to 79%) for 2 doses and 92% (95% CI: 85 to 95%) for 3 doses. Among immunocompetent patients, VE was 88% (95% CI: 87 to 90%) for 2 doses and 96% (95% CI: 83 to 99%) for 3 doses. CONCLUSION: Effectiveness of COVID-19 mRNA vaccines was lower for SOT recipients than immunocompetent people and those with other immunocompromising conditions. Among SOT recipients, vaccination with 3 doses of an mRNA vaccine led to substantially greater protection than 2 doses.

A c c e p t e d M a n u s c r i p t among immunocompetent people, generally with estimates of 85% or higher [1] [2] [3] [4] [5] [6] . However, lower estimates of VE against hospitalization have been reported among people with immunocompromising conditions [7, 8] . This is an area of concern, as immunocompromised people, especially those severely immunocompromised such as solid organ transplant (SOT) recipients, are at increased risk of severe illness with COVID-19 [9] .

Immunogenicity studies suggest that COVID-19 mRNA vaccines produce less robust immune responses among people who are immunocompromised [9] [10] [11] [12] [13] . Early clinical studies suggest this translates into lower VE for the prevention of severe COVID-19 among adults with immunocompromising conditions [7, 8, [14] [15] [16] . However, a greater understanding of VE for COVID-19 vaccines among immunocompromised populations is needed. Prior studies have largely pooled all patients with immunocompromising conditions together without consideration for the intensity of immunosuppression, producing VE results that may overestimate VE for the most severely immunocompromised people [8, 16] .

In the United States, initial recommendations for people with moderate-to-severe immunocompromising conditions were two doses of an mRNA COVID-19 vaccine; this recommendation was updated to three doses on August 12, 2021, with a fourth dose currently recommended at least 3 months after the third dose as a vaccine booster [17] . Understanding the clinical protection provided by mRNA vaccines in immunocompromised populations is critically important for several reasons, including: helping guide decisions on the prophylactic use of anti-SARS-CoV-2 monoclonal antibody therapies for vaccinated immunocompromised patients; informing recommendations regarding continued use of non-pharmaceutical preventative strategies, such as mask wearing, after vaccination; and informing recommendations for additional vaccine booster A c c e p t e d M a n u s c r i p t 7 doses [9, 14, 18] . In this analysis, we estimated VE against COVID-19 hospitalization for 2-dose and 3dose mRNA vaccine series among SOT recipients, a population that is typically severely immunocompromised, and therefore potentially susceptible to severe COVID-19 despite prior vaccination. We also estimated 2-dose and 3-dose mRNA VE among adults with other types of immunocompromising conditions.

This work was conducted as part of an ongoing prospective COVID-19 surveillance program by the Influenza and Other Viruses in the Acutely Ill (IVY) Network [8, 15] 

This work was determined to be a public health surveillance activity by all enrolling sites, Vanderbilt University Medical Center (coordinating center), and CDC (funder and government sponsor).

Adult patients aged 18 years and older hospitalized at 21 IVY Network hospitals between March 11 and December 15, 2021 were included. As previously described [8, 16] , and detailed in Supplementary Appendix B Section 1, case patients had COVID-19-like illness and a positive SARS-CoV-2 molecular (e.g., RT-PCR) or antigen test result in the clinical setting [8, 16] . COVID-19-like illness was defined as having one or more of the following: fever, cough, shortness of breath, loss of A c c e p t e d M a n u s c r i p t 8 taste, loss of smell, use of respiratory support for the acute illness, or new pulmonary findings on chest imaging consistent with pneumonia. Control patients included test-negative controls who were admitted with a COVID-19-like illness and tested negative for SARS-CoV-2 by a molecular assay, and syndrome-negative controls who were admitted without COVID-19-like illness and tested negative for SARS-CoV-2 by a molecular assay. In addition to clinical testing, nasal specimens were also collected from patients and tested for SARS-CoV-2 by RT-PCR at a central laboratory at Vanderbilt University Medical Center using standardized methods developed by CDC. Final case and control status was determined using both clinical testing and central laboratory results [8] . Thus, cases were patients hospitalized with laboratory confirmed, symptomatic COVID-19, and controls were patients hospitalized without COVID-19. SARS-CoV-2 detected in the central laboratory with a cycle threshold <32 also underwent viral whole genome sequencing at University of Michigan for lineage determination [8, 16] . Patients or their proxies were interviewed to obtain information about demographic characteristics, clinical history, and COVID-19 vaccination status, and structured medical record abstraction was used to collect information on chronic medical conditions and clinical outcomes [8, 16] .

Receipt of COVID-19 vaccine doses was ascertained by participant interview, hospital medical records, state immunization registries, vaccination record cards, and provider and pharmacy records. 

Data on immunocompromising conditions were collected via standardized medical record review.

Using these data, patients were categorized into one of three mutually exclusive categories of immune status at the time of hospital admission: Group 1: SOT recipient; Group 2: other immunocompromising condition [8] ; or Group 3: immunocompetent (details provided in Supplementary Appendix B Section 2). Older age was not considered an immunocompromising condition in this analysis. For SOT recipients, detailed information on type and date of organ transplant, organ transplanted (heart, lung, liver, pancreas, intestine, or mixed organs), immunosuppressive regimen at the time of hospital admission, and history of transplant rejection in the previous year were collected through detailed physician-level medical record review. SOT recipients were excluded from the analysis if they were not on immunosuppressive medications (e.g., due to renal graft failure) or the date of transplant was found to be after the illness onset date. 

VE against COVID-19 hospitalization was calculated using multivariable logistic regression. The dependent variable was case vs control status, with the control group including both test-negative and syndrome-negative controls. The primary independent variable was vaccination status classified into three groups, including unvaccinated (the reference group), vaccinated with 2 doses, or vaccinated with 3 doses. Models used to estimate VE included the following pre-specified covariables: admission date (categorized in biweekly intervals), US Department of Health and Human Services geographic region, age, sex, and race/ethnicity [8, 16] . VE was calculated as: [(1 -aOR) × 100], with the aOR representing the odds of vaccination (2 doses versus unvaccinated or 3 doses versus unvaccinated) among cases compared to controls derived from the logistic regression model. Separate VE estimates were calculated for each of the three immune status groups (SOT recipients, other immunocompromising conditions, immunocompetent). For other non-SOT immunocompromising conditions, stratified VE estimates were calculated for common immunocompromised subgroups, including patients with active hematologic malignancy, active solid organ malignancy, and either rheumatologic conditions or inflammatory bowel disease. As a sensitivity analysis to account for the potential of SOT recipients being hospitalized for less severe A c c e p t e d M a n u s c r i p t 11 COVID-19 than immunocompetent patients, VE estimates were calculated after restricting cases to those with hypoxemia at hospital admission, defined as SpO2 <92% or treated with supplemental oxygen within 24 hours of admission. All VE results were presented as pooled analyses including both COVID-19 mRNA vaccines available in the United States (BNT-162b2 and mRNA-1273). Twodose and 3-dose VE estimates were compared using the pwcompare function in Stata, with a 2-sided p-value <0.05 considered statistically significant.

In-hospital clinical outcomes among COVID-19 case patients were compared across the three immune status groups, stratified by vaccination status. Analyses were conducted using STATA (release 16; StataCorp) and RStudio (version 1.2). 

Among SOT recipients (group 1), VE against COVID-19 hospitalization for 2 mRNA vaccine doses was 29% (95% CI: -19 to 58%) and for 3 mRNA vaccine doses was 77% (95% CI: 48 to 90%), with a significant difference in VE between 2 doses and 3 doses (p=0.002) (Figure 2 ). Among patients with other immunocompromising conditions (Group 2), VE against COVID-19 hospitalization for 2 mRNA vaccine doses was 72% (95% CI: 64 to 79%) and for 3 doses was 92% (95% CI: 85 to 95%) [p<0.001 for 2 doses vs. 3-doses]. Among subgroups within Group 2, VE for 2 mRNA vaccine doses was 75% (95% CI: 62 to 84%) and for 3 vaccine doses was 91% (95% CI: 78 to 97%) for those with active solid organ cancer (p=0.02 for 2 doses vs. 3 doses); VE for 2 vaccine doses was 74% (95% CI: 57 to 85%) and for 3 vaccine doses was 97% (95% CI: 83 to 99%) for those with rheumatologic conditions or IBD A c c e p t e d M a n u s c r i p t 13 (p=0.012 for 2-doses vs. 3-doses); and VE for 2 doses was 61% (95% CI: 14 to 83%) and for 3 doses was 94% (95% CI: 72 to 98%) for those with active hematologic malignancies (p=0.013 for 2 doses vs.

(95% CI: 87 to 90%) and for 3 doses was 96% (95% CI: 83 to 99%) (p<0.001 for 2 doses vs. 3 doses).

VE results were similar after restricting COVID-19 cases to those with evidence of hypoxemia within 24 hours of hospital admission (Figure 2 ). Findings were also consistent in a post hoc analysis restricted to patients admitted after third dose authorization.

Among 227 SOT recipients hospitalized with COVID-19 with outcome data (3 missing), 38 (17%) patients died in the hospital before day 28, including 30/163 (18%) who were vaccinated (with 2 or 3 doses) and 8/64 (13%) who were unvaccinated (p=0.28). Among vaccinated cases, the severity of illness was generally greater for the SOT recipients and those with other immunocompromising conditions compared to immunocompetent patients, including for ICU admission (45% vs 32% vs 27%), invasive mechanical ventilation (21% vs 15% vs 13%), and in-hospital death within 28 days (18% vs 15% vs 10%) ( Table 3) . Among immunocompetent patients hospitalized with COVID-19, severe in-hospital outcomes were more common in unvaccinated patients compared vaccinated patients. However, among patients with immunocompromising conditions hospitalized with COVID-19, the proportion of patients who experienced severe outcomes was similar for those unvaccinated and vaccinated (Table 3 ).

In this multicenter, observational study of adults hospitalized in the US between March and December 2021, VE for mRNA COVID-19 vaccines against COVID-19-associated hospitalization was significantly lower for SOT recipients than for immunocompetent people and for those with other immunocompromising conditions. These results highlight that people with moderate-to-severe Additionally, these results highlight that other measures to reduce the risk of COVID-19 among SOT recipients should be considered, including vaccination of close contacts [19] , individual immune monitoring [20] , and infection prevention strategies such as face masking in public spaces and physical distancing.

Several studies have indicated that COVID-19 mRNA vaccination results in reduced immune response among SOT recipients on immunosuppressive medication regimens compared to immunocompetent patients [11, [21] [22] [23] [24] [25] [26] [27] . Results of the current study suggest that reduced immunogenicity observed in the SOT population does translate into lower protection against severe COVID-19. However, there is hope vaccination can provide important protection against severe COVID-19 for SOT recipients as mRNA vaccine doses elicit cellular and humoral responses in many SOT recipients, including kidney [28] , heart, and liver transplant recipients [29] . Increased VE against A c c e p t e d M a n u s c r i p t 15 COVID-19 hospitalization with a third mRNA vaccine dose among SOT recipients in this study is encouraging. Impaired immune responses in immunosuppressed patients can often be overcome to provide benefit from vaccination through strategies such as additional priming doses, boosters, and modifying vaccines (e.g., addition of adjuvants; increasing antigens) [30, 31] . However, immunosuppressive states are a heterogeneous range of conditions and treatments. Thus, the effects of vaccines likely vary by the severity and type of immunosuppression, and greater understanding of vaccine responses in the face of specific immunocompromising conditions is needed. For example, as shown in this study, SOT recipients appear to garner less protection from COVID-19 mRNA vaccine doses than people with some other immunocompromising conditions. From a vaccination policy perspective, immunosuppression has generally been considered binaryimmunosuppressed or not. As our understanding of vaccination in immunosuppressed hosts improves, a better approach may be to consider the mechanistic effect that a specific condition has on the immune system and clinical effectiveness data for mechanistically-rational subgroups of immunocompromising conditions [30] .

Prior studies evaluating vaccine performance in immunocompromised hosts have generally taken two approaches. One approach has been to focus on evaluating immunogenicity (without clinical outcomes) in specific immunocompromising conditions [32, 33] . These studies are valuable initial steps but must be paired with clinical effectiveness data. The second approach has been to utilize electronic health records to identify enough patients with electronic codes for immunocompromising conditions to complete vaccine effectiveness analyses [7, 34] . A c c e p t e d M a n u s c r i p t 16 The current study identified patients with a prior SOT and currently taking anti-rejection immunosuppressive medications as one specific subgroup of immunosuppression. We did this by leveraging the strengths of trained clinician investigators and a large hospital-based active surveillance program. Trained personnel collected accurate information on immunocompromising conditions, including the timing of immunosuppression in relation to vaccine receipt and onset of illness. We then applied modified immunosuppression algorithms developed by previous investigators to classify patients into groups relevant for VE evaluation [35, 36] . We then assessed for effect modification of VE across these groups and observed that lower VE in the large group traditionally labeled as "moderately-to-severely immunocompromised" was a weighted average of VE from many separate smaller groups and VE for SOT recipients was substantially lower than for patients with many other immunocompromising conditions. This study has limitations to consider. First, although this was a multicenter study that enrolled over 10,000 participants, the number of SOT recipients hospitalized with COVID-19 was modest (n=230), which prevented robust analyses evaluating factors that may be contributing determinants of VE for SOT patients, such as immunosuppressive medication regimen and time from organ transplant to vaccination. Second, the group of patients in this study classified as having other immunocompromising conditions (group 2) included a heterogeneous array of medical conditions associated with varying degrees of immunosuppression; this group, along with the immunocompetent group, provided a comparator for interpretation of the VE estimates for SOT recipients. Third, this study included only hospitalized patients; thus, we are unable to provide data on VE against less severe COVID-19, such as symptomatic disease not resulting in hospitalization.

Fourth, although potential confounders were included in multivariable models, residual confounding is possible in this observational study.

In conclusion, vaccine effectiveness of mRNA COVID-19 vaccines to prevent COVID-19associated hospitalization was lower for SOT recipients than immunocompetent people. Three doses of an mRNA COVID-19 vaccine provided substantially greater protection than two doses for SOT * Models were adjusted for calendar time of admission (in biweekly intervals), US Health and Human Services region, age group (18-49, 50-64, or ≥65 years), sex, and race and Hispanic ethnicity. † Post hoc p-value comparisons of vaccine effectiveness for 2 doses vs 3 doses of an mRNA vaccine were obtained using the pwcompare function in Stata § Defined as receiving supplemental oxygen support or having a documented oxygen saturation <92% within 24 hours of admission. This analysis was restricted to cases who met criteria for hypoxemia within 24 hours of admission and all control patients (i.e., including those with or without hypoxemia).

Comparative Effectiveness of Moderna

Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions -United States

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

Coverage and Estimated Effectiveness of mRNA COVID-19

Vaccines Among US Veterans

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years -COVID-NET, 13 States

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study

Effectiveness of 2-Dose Vaccination with mRNA COVID-19

Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults -Nine States

Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

Reduced humoral response to mRNA SARS-CoV-2

BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults -United States

Association Between mRNA Vaccination and COVID-19

COVID-19 Vaccines for Moderately to Severely Immunocompromised People

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Coronavirus disease 2019 vaccination in transplant recipients

Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients

Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)

Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients

Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants

Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients

Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients

Cellular and humoral immune response after mRNA-1273

SARS-CoV-2 vaccine in liver and heart transplant recipients

Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review

Influenza vaccination in immunocompromised populations: Strategies to improve immunogenicity

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis

Influenza Vaccination for Immunocompromised Patients: Systematic Review and Meta-analysis by Etiology

Influenza Vaccine Effectiveness Among Patients With Cancer: A Population-Based Study Using Health Administrative and Laboratory Testing Data From Ontario, Canada

Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States

Validation of a Method to Identify Immunocompromised Patients with Severe Sepsis in Administrative Databases

A c c e p t e d M a n u s c r i p t 19 from NHLBI and AHRQ, and fees from Endpoint for participating on a scientific advisory panel, Table 2 .A c c e p t e d M a n u s c r i p t 29 A c c e p t e d M a n u s c r i p t 32